Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down to $23.57

Enliven Therapeutics, Inc. (NASDAQ:ELVN) gapped down before the market opened on Tuesday . The stock had previously closed at $23.57, but opened at $23.09. Enliven Therapeutics shares last traded at $22.94, with a volume of 752 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ELVN. Robert W. Baird started coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price target for the company. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Finally, HC Wainwright initiated coverage on Enliven Therapeutics in a report on Monday, September 9th. They set a “buy” rating and a $37.00 target price for the company.

Enliven Therapeutics Price Performance

The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -12.21 and a beta of 1.09. The firm has a 50 day moving average price of $23.02 and a 200-day moving average price of $21.31.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $22.57, for a total transaction of $95,922.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Joseph P. Lyssikatos sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $22.49, for a total transaction of $269,880.00. Following the completion of the sale, the insider now owns 1,077,936 shares in the company, valued at approximately $24,242,780.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $22.57, for a total transaction of $95,922.50. The disclosure for this sale can be found here. Insiders sold 123,805 shares of company stock worth $3,068,192 over the last 90 days. 29.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently modified their holdings of ELVN. Quest Partners LLC grew its holdings in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after buying an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Enliven Therapeutics by 67.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after purchasing an additional 3,189 shares during the last quarter. EntryPoint Capital LLC acquired a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $167,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Enliven Therapeutics during the second quarter worth approximately $322,000. Finally, Blackstone Inc. acquired a new stake in shares of Enliven Therapeutics during the first quarter worth $443,000. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.